Pomerantz Law Firm Launches Investigation Into Zenas BioPharma, Inc. Investor Claims

Pomerantz Law Firm Investigates Zenas BioPharma Inc.

In a significant development for investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO), the Pomerantz Law Firm has initiated an investigation regarding potential claims related to securities fraud and other unlawful business practices by the company and its officers. This investigation has emerged in light of the firm's recent announcements concerning the efficacy of its drug obexelimab in treating Immunoglobulin G4-Related Disease (IgG4-RD).

On January 5, 2026, Zenas disseminated a press release touting results from the Phase 3 INDIGO trial for obexelimab. While the company labeled the findings as "positive," many analysts quickly disagreed, noting that the reported effectiveness of the drug fell short of the threshold necessary for commercial viability. The backlash was immediate, resulting in a staggering 51.86% drop in the company's stock price, translating to a loss of $17.89 per share, which left shares closing at $16.61 following the announcement.

The situation worsened the following day, January 6, 2026, during a conference call where Zenas's CEO acknowledged disappointment over the drug's hazard ratio—a key metric for gauging efficacy—stating, "[d]isappointed that the hazard ratio doesn't hit a number that many people were hoping for." This admission led to an additional decline in stock price, with shares dropping another 8.49%, closing at $15.20.

This rapid decline has understandably raised red flags among investors, prompting the Pomerantz Law Firm to act. The firm is renowned for its commitment to corporate accountability, particularly in the realm of securities class actions. With a history of successfully advocating for victims of securities fraud and corporate misconduct, Pomerantz is poised to represent the interests of Zenas investors who may have suffered financial harm.

If you believe you have been affected by the actions of Zenas and wish to obtain more information about the potential claims, Pomerantz encourages you to contact their representative, Danielle Peyton, directly at [email protected] or via telephone at 646-581-9980, ext. 7980.

It is worth noting that the Pomerantz Law Firm, with its offices in major cities including New York and London, has spent over 85 years championing the rights of shareholders and is recognized as one of the foremost firms in class-action litigation. Investors should remain vigilant and consider their options regarding possible class actions stemming from Zenas's recent troubles.

While the investigation is currently underway, the outcomes for Zenas BioPharma and its investors are still uncertain. However, the legal efforts spearheaded by Pomerantz signify a crucial step towards potential accountability within the biotech firm. As always, investors are advised to remain informed about the developments in this case and to engage with responsible legal representation if they feel their investments have been compromised.